Thursday, January 23, 2020
9:54 AM EST – HLS Therapeutics Inc. : Announced that its New Drug Submission for PERSERIS®, a novel long-acting injectable risperidone product for the treatment of schizophrenia was accepted for review by Health Canada on January 23, 2020. HLS is seeking approval for PERSERIS with an indication for the treatment of schizophrenia in adults. HLS has in-licensed the exclusive rights to PERSERIS for the Canadian market from Indivior PLC. PERSERIS is not approved in Canada. HLS Therapeutics Inc. (T.HLS) shares were unchanged at 23.45.
Stocks in Play: HLS Therapeutics Inc., Thu, 23 Jan 2020 09:57:58 EST